Regeneron/REGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Regeneron

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Ticker

REGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Tarrytown, United States

Employees

13,677

Regeneron Metrics

BasicAdvanced
$114B
Market cap
31.23
P/E ratio
$33.85
EPS
0.12
Beta
-
Dividend rate
$114B
0.12
6.403
4.396
10.016
10.016
55.95%
7.74%
15.28%
31.23
8.62
4.22
4.39
28.75
5.90%
-7.95%
12.51%
-1.23%

What the Analysts think about Regeneron

Analyst Ratings

Majority rating from 29 analysts.
Buy

Regeneron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
22.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.1B
-8.42%
Net income
$722M
-37.74%
Profit margin
22.95%
-32.02%

Regeneron Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$10.24
$11.59
$11.86
$9.55
-
Expected
$9.84
$10.72
$10.73
$10.09
$10.59
Surprise
4.03%
8.13%
10.53%
-5.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Regeneron stock?

Regeneron (REGN) has a market cap of $114B as of July 03, 2024.

What is the P/E ratio for Regeneron stock?

The price to earnings (P/E) ratio for Regeneron (REGN) stock is 31.23 as of July 03, 2024.

Does Regeneron stock pay dividends?

No, Regeneron (REGN) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Regeneron dividend payment date?

Regeneron (REGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Regeneron?

Regeneron (REGN) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Regeneron stock

Buy or sell Regeneron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing